Advertisement

Intensive Care Medicine

, Volume 42, Issue 3, pp 429–431 | Cite as

Our paper 20 years later: the unfulfilled promises of nebulised adrenaline in acute severe asthma

  • Fekri AbrougEmail author
  • Fahmi Dachraoui
  • Lamia Ouanes-Besbes
My Paper 20 Years Later

Introduction

Asthma is a prevalent non-communicable disease affecting around 300 million persons worldwide with an age-standardized death rate that decreased by no less than 41 % between 1990 and 2013 [1]. However, the majority of remaining asthma deaths (67 %) are deemed preventable especially in young asthmatics [2]. Childhood asthma has indeed become more frequent and severe. Preventable asthma mortality is related to poor adherence to treatment, inadequate assessment of asthma severity and that of ongoing attacks leading to implementing non-appropriate treatment [3].

Inhaled selective β2 agonists, systemic corticosteroids and supplemental oxygen represent the mainstay for the treatment of acute asthma, with addition of ipratropium bromide and magnesium sulfate in severe cases [4]. Short-acting selective β2 agonists and systemic corticosteroids act through the relief of the main components of bronchial obstruction in acute asthma: the muscle-related bronchial narrowing and the...

Keywords

Asthma Salbutamol Salmeterol Terbutaline Formoterol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with ethical standards

Conflicts of interest

None.

Supplementary material

134_2016_4210_MOESM1_ESM.docx (21 kb)
Supplementary material 1 (DOCX 21.3 kb)

References

  1. 1.
    GBD 2013 Mortality and Causes of Death Collaborators (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet 385:117–171CrossRefGoogle Scholar
  2. 2.
    Anagnostou K, Harrison B, Iles R, Nasser S (2012) Risk factors for childhood asthma deaths from the UK eastern region confidential enquiry 2001–2006. Prim Care Respir J 21:71–77CrossRefGoogle Scholar
  3. 3.
    Soto-Campos JG, Plaza V, Soriano JB, Cabrera-Lopez C, Almonacid-Sanchez C, Vazquez-Oliva R, Serrano J, Ballaz-Quincoces A, Padilla-Galo A, Santos V (2013) Causes of death in asthma, COPD and non-respiratory hospitalized patients: a multicentric study. BMC Pulm Med 13:73CrossRefGoogle Scholar
  4. 4.
    Custovic A, Johnston SL, Pavord I, Gaga M, Fabbri L, Bel EH, Le Souef P, Lotvall J, Demoly P, Akdis CA, Ryan D, Makela MJ, Martinez F, Holloway JW, Saglani S, O’Byrne P, Papi A, Sergejeva S, Magnan A, Del Giacco S, Kalayci O, Hamelmann E, Papadopoulos NG (2013) EAACI position statement on asthma exacerbations and severe asthma. Allergy 68:1520–1531CrossRefGoogle Scholar
  5. 5.
    Salmeron S, Brochard L, Mal H, Tenaillon A, Henry-Amar M, Renon D, Duroux P, Simonneau G (1994) Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study. Am J Respir Crit Care Med 149:1466–1470CrossRefGoogle Scholar
  6. 6.
    Rowe BH, Sevcik W, Villa-Roel C (2011) Management of severe acute asthma in the emergency department. Curr Opin Crit Care 17:335–341CrossRefGoogle Scholar
  7. 7.
    Hanania NA, Dickey BF, Bond RA (2010) Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Curr Opin Pulm Med 16:1–5CrossRefGoogle Scholar
  8. 8.
    Hanania NA, Sharafkhaneh A, Barber R, Dickey BF (2002) Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med 165:1353–1358CrossRefGoogle Scholar
  9. 9.
    Elatrous S, Elidrissi H, Trabelsi H, Boujdaria R, Boussarsar M, Ouannes L, Bouzouita K, Nouira S, Abroug MF (1997) Dose-effect of epinephrine nebulization in asthma: a comparative study versus salbutamol. Rev Pneumol Clin 53:187–191PubMedGoogle Scholar
  10. 10.
    Besbes-Ouanes L, Nouira S, Elatrous S, Knani J, Boussarsar M, Abroug F (2000) Continuous versus intermittent nebulization of salbutamol in acute severe asthma: a randomized, controlled trial. Ann Emerg Med 36:198–203CrossRefGoogle Scholar
  11. 11.
    Baldwin DR, Sivardeen Z, Pavord ID, Knox AJ (1994) Comparison of the effects of salbutamol and adrenaline on airway smooth muscle contractility in vitro and on bronchial reactivity in vivo. Thorax 49:1103–1108CrossRefGoogle Scholar
  12. 12.
    Becker AB, Nelson NA, Simons FE (1983) Inhaled salbutamol (albuterol) vs injected epinephrine in the treatment of acute asthma in children. J Pediatr 102:465–469CrossRefGoogle Scholar
  13. 13.
    Abroug F, Nouira S, Bchir A, Boujdaria R, Elatrous S, Bouchoucha S (1995) A controlled trial of nebulized salbutamol and adrenaline in acute severe asthma. Intensive Care Med 21:18–23CrossRefGoogle Scholar
  14. 14.
    Coupe MO, Guly U, Brown E, Barnes PJ (1987) Nebulised adrenaline in acute severe asthma: comparison with salbutamol. Eur J Respir Dis 71:227–232PubMedGoogle Scholar
  15. 15.
    Zeggwagh AA, Abouqal R, Madani N, Abidi K, Moussaoui R, Zekraoui A, Kerkeb O (2002) Comparative efficiency of nebulized adrenaline and salbutamol in severe acute asthma. A randomized, controlled prospective study. Ann Fr Anesth Reanim 21:703–709CrossRefGoogle Scholar
  16. 16.
    Adoun M, Frat JP, Dore P, Rouffineau J, Godet C, Robert R (2004) Comparison of nebulized epinephrine and terbutaline in patients with acute severe asthma: a controlled trial. J Crit Care 19:99–102CrossRefGoogle Scholar
  17. 17.
    Plint AC, Osmond MH, Klassen TP (2000) The efficacy of nebulized racemic epinephrine in children with acute asthma: a randomized, double-blind trial. Acad Emerg Med 7:1097–1103CrossRefGoogle Scholar
  18. 18.
    Rodrigo GJ, Nannini LJ (2006) Comparison between nebulized adrenaline and beta2 agonists for the treatment of acute asthma. A meta-analysis of randomized trials. Am J emerg med 24:217–222CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg and ESICM 2016

Authors and Affiliations

  • Fekri Abroug
    • 1
    • 2
    Email author
  • Fahmi Dachraoui
    • 1
    • 2
  • Lamia Ouanes-Besbes
    • 1
    • 2
  1. 1.Intensive Care UnitCHU Fatouma BourguibaMonastirTunisia
  2. 2.Research Laboratory LR12SP15University of MonastirMonastirTunisia

Personalised recommendations